Theresa Ruf, Rafaela Kramer, Andrea Forschner, Ulrike Leiter, Friedegund Meier, Lydia Reinhardt, Pia Dücker, Carolin Ertl, Dirk Tomsitz, Julia K Tietze, Ralf Gutzmer, Evelyn Dabrowski, Lisa Zimmer, Anja Gesierich, Sarah Zierold, Lars E French, Thomas Eigentler, Teresa Amaral, Lucie Heinzerling
BACKGROUND: Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10% of cases. An evidence-based analysis of the effectiveness of second-line immunosuppressive agents with regard to irAE and tumor control is lacking. METHODS: The international web-based Side Effect Registry Immuno-Oncology (SERIO; https://serio-registry...
March 27, 2024: European Journal of Cancer